title: Efficacy of fenbendazole granules and pyrantel pamoate suspension against Toxocara canis in greyhounds housed in contaminated runs.
abstract: The efficacy of fenbendazole granules against Toxocara canis in naturally infected greyhounds housed in contaminated environments was evaluated. Eight pens, each containing three to seven greyhounds, 3-12 months of age, were randomly allotted into two treatment groups. Greyhounds in Group 1 were treated with fenbendazole granules mixed in their feed at 50 mg/kg/day for 3 consecutive days once a month for 4 months. Greyhounds in Group 2 were treated with pyrantel pamoate suspension at 5.0 mg/kg per os once a month for 4 months. Quantitative fecal examinations were performed on days 0, 10 and then on the first day of each monthly treatment. Greyhounds administered fenbendazole had fecal egg count reductions (FECRs) of 95.8 and 99.8% at 10 and 31 days following initial treatment, respectively. Greyhounds administered pyrantel pamoate had FECRs of 85.8 and 88.3% at 10 and 31 days after the first treatment, respectively. T. canis fecal egg counts conducted from Day 31 through Day 128 were significant lower in those greyhounds administered fenbendazole as compared to greyhounds administered pyrantel pamoate. Fenbendazole produced FECRs in greyhounds from Day 31 through Day 128 by 96.8-99.8%. Pyrantel pamoate reduced fecal egg counts during the same time period 71.4-98.3%.
authors.affiliation: Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan 66506, USA. dryden@vet.ksu.edu
authors.forename: M W
authors.initials: MW
authors.lastname: Dryden
authors.forename: R K
authors.initials: RK
authors.lastname: Ridley
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000469:parasitology / Q000517:prevention & control*; D004285:Dogs; D005243:Feces / Q000469:parasitology; D005273:Fenbendazole / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D010270:Parasite Egg Count / Q000662:veterinary; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D013535:Suspensions; D017166:Toxocara canis / Q000187:drug effects*; D014120:Toxocariasis / Q000517:prevention & control*
chemical_list: D013535:Suspensions; D005273:Fenbendazole; D011716:Pyrantel Pamoate